Lymphangioleiomyomatosis (LAM): Molecular insights lead to targeted therapies
Authors:
- Connie G. GlasgowCGConnie G. Glasgow
- Wendy K. SteagallWSWendy K. Steagall
- Angelo Taveira-DaSilvaATAngelo Taveira-DaSilva
- Gustavo Pacheco-RodriguezGPGustavo Pacheco-Rodriguez
- Xiong CaiXCXiong Cai
- Souheil El-ChemalySESouheil El-Chemaly
- Marsha MosesMMMarsha Moses
- Thomas DarlingTDThomas Darling
- Joel MossJMJoel Moss
- 1 July 2010
- journal article
- Published by Elsevier in Respiratory Medicine
- Vol. 104 (Suppl 1) , S45-S58
Abstract
No abstract availableKeywords
This publication has 163 references indexed in Scilit:
- Phosphatidic acid signaling to mTOR: Signals for the survival of human cancer cellsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- Estrogen promotes the survival and pulmonary metastasis of tuberin-null cellsProceedings of the National Academy of Sciences, 2009
- The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1Science, 2008
- The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2Molecular and Cellular Biology, 2008
- Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttlingGenes & Development, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- A positive feedback loop couples Ras activation and CD44 alternative splicingGenes & Development, 2006
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Rheb is a direct target of the tuberous sclerosis tumour suppressor proteinsNature Cell Biology, 2003